85 results about "Drug toxicity" patented technology

The invention discloses a bacteriophage lyase and application thereof, and particularly relates to a bacteriophage lyase with an amino acid sequence as shown in SEQ INNO.2. The bacteriophage lyase can inhibit the growth of escherichia coli, staphylococcus and salmonella, can be used as an antibacterial substance in splitting gram-negative bacteria and can be used for preparing drugs for resisting gram-negative bacteria. The lyase can be used independently or compounded with other substances, the use concentration of antibiotics can be reduced by combining the lyase with the antibiotics, toxic and side effects (such as renal toxicity of polymyxin) of drugs are reduced, and meanwhile, generation of bacterial drug resistance is delayed. After the lyase and the chitosan are combined for use, remarkable antibacterial activity is generated, the antibacterial effect can be achieved without pre-treatment on bacteria, and the practicability is improved.

The invention discloses a novel compound rapid surface anesthetic and a preparation method thereof, and belongs to the field of pharmaceutical preparations. According to the anesthetic, core anesthetic components of lidocaine and tetracaine are compounded with propylene glycol-laurocapram synergistic penetration enhancer, menthol auxiliary penetration enhancer, carbomer 980 gel matrix, triethanolamine pH regulator, glycerol humectant, panthenol soothing agent, purified water and the like, a surface smearing agent is prepared through a specific process, and the anesthetic can be administered in combination with an iontophoresis technology. Compared with the existing surface anesthetic for the cosmetic surgery, the surface anesthetic disclosed by the invention solves the problems of slow effect taking and poor effect, can realize rapid penetration of local skin, has short anesthesia effect taking time, long duration and good effect, has no obvious irritation to the skin, has good product stability, can effectively reduce the drug toxicity, and has a good application prospect. The device is suitable for surface anesthesia of non-surgical medical beauty items such as skin beauty, laser treatment and water-light micro-needles.

The invention relates to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating Parkinson's disease, namely tremor syndrome of traditional Chinese medicine, which comprises the following raw materials by weight: 390-470g of liver calming and wind calming medicine, 140-160g of radix rehmanniae, 280-320g of radix paeoniae alba, 840-960g of first decoction medicine, 390-450g of blood activating and qi regulating and tendon and collateral dredging medicine, and 305-355g of antidote. The traditional Chinese medicine composition has remarkable effects of relaxing tendons and detoxifying, and calming endogenous wind and arresting fibrillation, can play a role in solving the problems of head shaking, limb tremor, muscle stiffness, dyskinesia and the like caused by liver wind internal movement and kidney deficiency and toxic damage of Parkinson's disease, and can nourish liver and kidney, relieve tendon and vessel contracture and relieve pain due to the synergistic effect of various traditional Chinese medicinal materials contained in the traditional Chinese medicine composition. The traditional Chinese medicine composition is especially suitable for Parkinson patients with liver-wind internal movement and kidney deficiency and toxicity loss, and can gradually improve the neurotransmitter level in the brain after being taken. The traditional Chinese medicine composition has an outstanding detoxification effect, can effectively remove accumulation of pathological products such as phlegm and blood stasis in the body of the Parkinson's disease patient, prevents phlegm and blood stasis from generating toxins, and can relieve medicine poison generated by long-term medicine taking of the patient.

The present invention relates to an antibody-drug conjugate represented by formula (I) having an oxacycloalkyl-substituted camptothecin derivative as a drug toxic moiety, wherein the definitions of each group in the formula are as described in the specification, and the antibody-drug conjugate has a significant antitumor effect. [Formula 1] JPEG2026502963000098.jpg54170

The present application relates to the technical field of health care products, in particular to a pelvic floor muscle repairing composition containing supermolecular tightening Dropsordry and a preparation method thereof, which comprises the following components in mass fraction: 10-14 parts of protein composition, 20-24 parts of chitosan modified Dropsordry, 5-7 parts of freeze-dried powder of Lactobacillus bulgaricus, 10-12 parts of hyaluronic acid, 6-8 parts of glycine and 15-17 parts of proline; each part of the protein composition comprises 20-30 parts of myosin, 30-34 parts of actin, 5-10 parts of hydrolyzed collagen and 240-280 parts of deionized water. The pelvic floor muscle repairing composition can reduce drug toxicity, reduce the amount of drug administration, continuously supplement the required elements of the body during treatment, and quickly relieve the constipation problem caused by the functional damage of the pelvic floor muscle.

The present application relates to providing a doxorubicin-loaded anti-tumor hemostatic microsphere constructed by a simple, safe and low-cost method and its preparation and application, the doxorubicin-loaded anti-tumor hemostatic microsphere comprises alginate, hemostatic component A, doxorubicin or doxorubicin liposome, crosslinking agent, the hemostatic component A is selected from one or more of carboxymethyl chitosan, hyaluronic acid, collagen, silk fibroin, solve the practical pain point problems such as easy bleeding in tumor resection surgery, large toxicity of chemotherapeutic drugs, large drug dose, frequent drug administration, etc., realize rapid hemostasis in operation, postoperative precise targeted drug delivery, reduce toxic side effects, long-acting drug sustained release, at the same time, all components of the system are safe and reliable, and have good biocompatibility.

The invention relates to the technical field of medicine, and discloses a raltitrexed composition and a preparation method thereof.The raltitrexed composition is prepared by taking a full-biodegradable amphiphilic polymer grafted with hydrophilic chitosan and hydrophobic polylactic acid as a carrier, a raltitrexed drug is embedded in a micelle core of a copolymer by virtue of the large specific surface area and strong adsorption capacity of the carbon nano tube, the targeting function of folic acid and the hydrophobicity of a long chain of polylactic acid under the action of pi-pi action and electrostatic adsorption with the carbon nano tube and chitosan in the composition, so that the encapsulation efficiency is greatly improved; raltitrexed molecules contain elements such as O, N and S, hydrogen bonds can be easily formed by the Raltitrexed molecules and the amphiphilic copolymer, the drug release time can be prolonged through a hydrophobic end polylactic acid side chain, the purpose of slow release is achieved, drug toxicity and adverse reactions are reduced, and the prepared composition is stable in release and ideal in slow release effect.

The present invention discloses, in one embodiment, a method of using human induced pluripotent stem cells to generate three-dimensional human organ tissue for therapeutic drug toxicity and discovery⋅. In one embodiment, a high throughput microtiter plate is loaded with both wild type and Rett disease 3D spheroids and exposed to a drug library, and activity is measured and analyzed for disease rescue to wild type cell behavior.

The invention discloses a method for activating a copper-indium-sulfur thin film through selenium ions at a low temperature and a solar cell based on the thin film. According to the method, the CuInS2 thin film prepared by spin coating is treated by adopting the selenium ion solution, so that diffusion and distribution of selenium ions in the CuInS2 thin film prepared by spin coating are accurately regulated and controlled, carrier recombination is inhibited, and the CuInS2 thin film which is better in energy band structure, lower in defect state density and better in crystallinity and morphology is obtained; and the solar cell with high efficiency (more than 10.0%) is prepared on the basis. The method disclosed by the invention has the advantages of simplicity in operation, low equipment requirement, low cost, low toxicity of used drugs and small damage of a treatment technology to a thin film structure, overcomes the defects of complicated operation, high equipment requirement, damage to a thin film crystal structure by treatment in a high-temperature environment and the like in the prior art, and opens up a new way for high-performance and low-cost inorganic thin film photovoltaics.

The invention discloses a kidney organoid culture and multifunctional detection integrated micro-fluidic chip, which is characterized in that a first chip (top layer) is provided with six independent cell culture chambers, the bottom is provided with a porous membrane, glomerular cells differentiated by human induced pluripotent stem cells are inoculated, and a blood filtration function is simulated; the second chip (middle layer) is provided with a raw urine-like collecting chamber, and a porous membrane is used for receiving the filtrate and detecting final urine-like components; and the third chip (bottom layer) is inoculated with vascular endothelial cells to simulate renal tubule reabsorption and blood purification processes. According to the invention, glomerular filtration and renal tubule reabsorption full-function chains are coupled, and the limitation of single function simulation is broken through; the parallel culture room supports synchronous drug toxicity testing or disease modeling; a multi-valve dynamic control system can accurately simulate pathological microenvironments such as high glucose and renal toxicity; and in-situ multi-parameter real-time analysis is realized through three paths of detection outlets. The chip provides a highly bionic in-vitro platform for drug screening, diabetic nephropathy mechanism research and kidney injury model construction.

The invention belongs to the technical field of drug toxicity prediction, and particularly relates to a drug toxicity prediction method based on metabolism guidance. The invention aims to guide a prodrug or a non-toxic substance through a metabolism method and consider the toxicity of the prodrug or the non-toxic substance in the metabolic process (for example, the prodrug is converted into an effective component in the metabolic process), so as to predict the potential toxicity of the prodrug or the non-toxic substance. By means of the guidance of metabolism, it is desirable to accurately predict whether or not a prodrug will generate toxicity in the body. In the technical scheme provided by the invention, molecules are learned by using different characterization modes for the molecular map, so that different features under different levels and different segmentation methods can be captured. Through the guidance of the metabolic diagram, the reactants can obtain product-related attributes for explaining the toxicity change generated in the metabolic process of the reactants.

The invention relates to the technical field of traditional Chinese medicine extract fermentation, and provides a microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method for treating AIDS and application of microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method.The microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method comprises the steps that microspore ganoderma lucidum strains and herba houttuyniae fermentation liquor are co-fermented, beta-cyclodextrin-selenocystine of a specially-made additive is combined, and the microspore ganoderma lucidum immune protein is obtained; the problems that in traditional AIDS treatment, latent infection cells are difficult to remove, toxic and side effects of drugs are remarkable, and the reconstruction efficiency of an immune system is low are effectively solved, experiments prove that the fermentation product can activate the immune system, the cell number and the dendritic cell maturity are remarkably improved, and the curative effect is good. Meanwhile, the multi-target antiviral effect is achieved by blocking virus envelope combination, inhibiting reverse transcriptase activity and inducing latent infection cell apoptosis; the anti-oxidation and anti-inflammatory characteristics can reduce the risk of opportunistic infection, reduce the toxic damage of antiviral drugs to liver, kidney and intestinal tracts, and provide a new scheme for comprehensive treatment of AIDS and nutrition support of patients.

The invention relates to the technical field of organoid culture, in particular to a construction method and application of a kidney organoid model. Comprising the following steps: S1, carrying out digestion and flow sorting on renal cortex tissues to obtain renal stem cells; s2, carrying out plane culture on the kidney stem cells to obtain kidney epithelial progenitor cells; s3, performing three-dimensional culture on the renal epithelial progenitor cells to obtain the kidney organ model. According to the method, an adult renal cortex tissue is taken as a starting cell source, a kidney organ model with mature near-end and far-end renal tubule phenotypes is efficiently constructed through an optimized plane amplification and three-dimensional induction culture system, and the formation of kidney organs can be efficiently induced in a short time; the finally obtained kidney organ model can be used for simulating acute kidney injury in vitro, and an efficient tool is provided for kidney disease mechanism research, drug toxicity screening and personalized treatment model construction.

The invention provides siRNA for inhibiting LPA gene expression and a conjugate thereof, the siRNA comprises a positive-sense strand and an antisense strand, the positive-sense strand comprises a nucleotide sequence I, and the antisense strand comprises a nucleotide sequence II; each nucleotide in the nucleotide sequence I and the nucleotide sequence II is modified or unmodified nucleotide; the nucleotide sequence I and the nucleotide sequence II are at least partially reversely complementary to form a double-stranded region; the nucleotide sequence I is basically consistent with a first nucleotide sequence, and the first nucleotide sequence is a nucleotide sequence of which the length is at least 15 nucleotides in mRNA expressed by the LPA gene. The siRNA as well as the conjugate and the pharmaceutical composition thereof provided by the invention have strong inhibitory ability on LPA genes, can significantly reduce the expression quantity of LPA mRNA, and are low in drug toxicity.

The application relates to the technical field of medicines, and discloses a composition of raltitrexed and a preparation method thereof. The composition of raltitrexed is a full-biodegradable amphiphilic polymer with hydrophilic chitosan and hydrophobic polylactic acid grafted as a carrier, and the composition is combined with carbon nanotubes and chitosan through pi-pi interaction and electrostatic adsorption. The carbon nanotubes have a large specific surface area and strong adsorption capacity, the folate has a targeting function, and the polylactic acid long chain has hydrophobicity. The raltitrexed drug is embedded in the micelle core of the copolymer, so that the encapsulation rate is greatly improved. The raltitrexed molecule contains O, N, S and other elements, can easily form a hydrogen bond with the amphiphilic copolymer, the hydrophobic end polylactic acid side chain can prolong the drug release time, achieve the purpose of slow release, reduce the drug toxicity and adverse reactions, the prepared composition is relatively stable in release, and the slow release effect is relatively ideal.

Provided is a method for producing a skin organoid, the method comprising: a step for performing a first culture of a primary skin cell in a first medium with at least one support among an extracellular matrix (ECM) and polyethylene glycol (PEG) to form a first skin organoid; and a step for performing a second culture of the first skin organoid in a second medium. In addition, the present disclosure provides: a skin organoid cultured by the method described above, the skin organoid having a round, spherical, three-dimensional shape and comprising a center portion, which is densely packed with cells, a stratum corneum formed on the outside of the center portion, and a hair root, wherein the cells can move from the center portion to the stratum corneum; and a method for evaluating drug toxicity by using same.

The invention belongs to the technical field of toxicological evaluation, and discloses a photoresponsive liver chip system for evaluating drug immunotoxicity, which comprises a liver chip with a multilayer structure, a photoresponsive immune cell elimination reagent and an illumination device. The invention also discloses an application of the photoresponsive liver chip system in drug immunotoxicity evaluation, which comprises the following steps: firstly, in a state that the photoresponsive immune cell elimination reagent is not activated, performing a first round of toxicity detection on a to-be-detected drug to obtain baseline toxicity data; then, activating a reagent through illumination, and specifically eliminating immune cells in the chip; then carrying out a second round of toxicity detection; the immunotoxicity contribution of the to-be-detected medicine is accurately evaluated by comparing the difference of two rounds of toxicity detection data. The method realizes sequential resolution evaluation on the direct toxicity and the immune-mediated toxicity of the drug on the same biological sample, overcomes the defects that a traditional method is tedious in operation and cannot distinguish toxicity sources, and has the advantages of rapidness, accuracy and high throughput.

This invention provides an siRNA for inhibiting MSTN gene expression, its conjugates, and their applications. The siRNA comprises a sense strand and an antisense strand, wherein the sense strand comprises nucleotide sequence I, and the antisense strand comprises nucleotide sequence II; each nucleotide in nucleotide sequence I and nucleotide sequence II is a modified or unmodified nucleotide. The siRNA, its conjugates, and the pharmaceutical composition provided by this invention exhibit strong inhibitory activity against the MSTN gene, significantly reducing the expression level of MSTN mRNA, and have low drug toxicity.

The invention discloses boron-rich magnetic nanoparticles and a preparation method and application thereof.The boron element content of the boron-rich magnetic nanoparticles is as high as 9-15 wt%, the boron-rich magnetic nanoparticles are prepared through a one-step solvothermal method, an iron oleate precursor, boric acid, phenyl ether and polyethylene glycol dicarboxylic acid are mixed, and then the mixture is subjected to a three-stage temperature programming reaction at the temperature of 90-120 DEG C, 180-220 DEG C and 250-270 DEG C to obtain the boron-rich magnetic nanoparticles; the prepared boron-rich nanoparticles are uniform in particle size and good in dispersity, have both high boron loading and superparamagnetism, and can significantly improve the tumor killing efficiency of BNCT and reduce the drug toxicity; the superparamagnetism can realize active targeting delivery guided by an external magnetic field, and the magnetic resonance imaging contrast agent can be used for avoiding the risk of magnetic agglomeration at the same time; fluorescence labeling and cell membrane or specific cell membrane protein modification are easily performed on the surfaces of the particles, so that the treatment effect is enhanced, and diagnosis and treatment integration guided by multi-modal imaging is realized; the boron-rich nanoparticles are simple and convenient in preparation process and easily available in raw materials, and have wide application prospects in tumor boron neutron capture therapy drugs.

An in vitro construct useful for toxicity testing is provided, comprising: a three-dimensional (3D) scaffold comprising silk fibroin and having a crosslinked porous matrix; and stem cells adherent to the 3D scaffold. In some embodiments, the stem cells adherent to the 3D scaffold maintain stable mitochondrial DNA in long term culture. In some embodiments, the stem cells are urine stem cells.

The invention relates to the field of animal models, in particular to a method for constructing a chronic tympanic membrane perforation rat model. The construction method comprises the following steps: under a microscope, perforating a rear quadrant of a tympanic membrane of a unilateral ear of a rat, embedding a gelatin sponge into the perforated part for a period of time, and then removing the gelatin sponge to obtain a chronic tympanic membrane perforated rat model; wherein the gelatin sponge is a gelatin sponge infiltrated with a drug solution, and the drug solution is a dexamethasone solution. According to the construction method of the chronic tympanic membrane perforation rat model, the success rate of modeling can be increased on the basis of reducing the death rate of animals, animal waste caused by drug toxicity and the risk of cancerogenic substance exposure of experimenters are reduced, and the construction method has important significance in tympanic membrane perforation research.

The present invention relates to an antibody-drug conjugate represented by formula (I) having a haloalkyl-substituted camptothecin derivative as a drug toxic moiety, wherein the definitions of each group in the formula are as described in the specification, and the antibody-drug conjugate has a significant antitumor effect. [Formula 1] JPEG2026501617000115.jpg57170

The application discloses a use of piperacillin sodium in preparation of an antitumor drug. The piperacillin sodium has a good cell proliferation inhibiting effect on various tumors, especially malignant tumors, and has no drug toxicity on normal non-tumor cells, and is safe.

The application discloses an IL12 mutant fusion protein and application thereof. Specifically disclosed are a fusion protein comprising an antibody binding to human PD1 and an IL12 mutant protein and a preparation method and therapeutic use thereof, wherein the IL12 mutant protein is obtained by mutation and modification of a wild-type P40 subunit. The fusion protein of the application has reduced binding capacity to an IL12 receptor, reduced drug toxicity of IL12, and obviously improved drugability of a cytokine. Meanwhile, through the specificity of the antibody, the fusion protein effectively enhances the targeting of the cytokine, weakens the potential toxicity of the cytokine, can exert the dual functions of the PD1 antibody and the IL12 cytokine, and thus has better anti-tumor potential. The fusion protein of the application can obviously inhibit tumor growth, has high anti-tumor effect, can prolong the half-life, reduce the administration frequency, has high safety, and has good clinical transformation value and broad application prospect.

This invention relates to a small molecule compound composition and its applications, belonging to the field of biotechnology. The small molecule compound composition of this invention includes NU7441, GW9662, and D609, or their stereoisomers. This invention is the first to discover that this small molecule compound combination can effectively inhibit oxidative damage to corneal epithelial cells caused by hyperosmolarity and significantly improve the survival rate of corneal epithelial cells. In vivo animal experiments show that, compared with the control group, the experimental group of mice injected with scopolamine-induced dry eye model mice, given eye drops containing the small molecule compound combination, showed significantly reduced corneal defects and increased tear secretion. The small molecule compound combination can effectively prevent corneal epithelial damage, has high efficacy, and no obvious drug toxicity. This small molecule compound combination may become a potent and effective drug for the clinical treatment of dry eye in the future.

The invention discloses a traditional Chinese medicine composition which comprises the following medicinal materials in terms of 50 preparation units: 60-100 parts of pseudo-ginseng, 60-100 parts of vinegar-processed rhizoma corydalis, 20-60 parts of starfish, 20-60 parts of ground beeltle, 5-15 parts of processed semen strychni, 10-30 parts of safflower, 1-20 parts of vinegar-processed frankincense, 1-20 parts of vinegar-processed myrrh, 1-10 parts of borneol and 0.1-1 part of artificial musk. The invention further discloses a preparation method of a tincture of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating acute and chronic falling trauma, neck, shoulder, waist and knee pain or arthralgia. The traditional Chinese medicine composition disclosed by the invention has the effects of relaxing muscles and tendons, promoting blood circulation, dredging collaterals, dissipating blood stasis, diminishing swelling and relieving pain. Pharmacodynamic studies show that the traditional Chinese medicine composition disclosed by the invention takes effect quickly and has a good curative effect when being used for treating symptoms such as traumatic injuries, blood stasis swelling and swelling and red and swollen injuries. The traditional Chinese medicine composition disclosed by the invention effectively relieves the injury condition of a tested animal, and is free of irritation and sensitization to the tested animal in a skin medication toxicity test.

The present application relates to the technical field of biological medicine, in particular to the application of Cdr1 and Mdr1 double-target inhibitor combined with azole drugs in the preparation of antifungal drugs. Based on the compound shown in formula (I) can be used as Cdr1 and Mdr1 double-target inhibitor, the inhibitory effect of the compound on Candida albicans, Candida auris, Candida glabrata, Candida tropicalis, Trichophyton rubrum and Trichophyton indiana combined with azole drugs was further evaluated. The results show that the compound shown in formula (I) itself has no obvious antibacterial activity on various fungi, but can reverse the drug resistance of Cdr1 and Mdr1 overexpression drug-resistant fungi. The combination of the compound with azole drugs can synergistically inhibit the activity of Candida albicans, Candida auris, Candida glabrata, Candida tropicalis, Trichophyton rubrum and Trichophyton indiana, effectively reduce the therapeutic dose of azole drugs, and the drug toxicity is small. Therefore, the compound shown in formula (I) can improve the antifungal effect of azole drugs and reduce the drug resistance of azole drugs.

The invention discloses a busulfan nano-micelle, a freeze-dried powder injection thereof, a preparation method of the freeze-dried powder injection and application of the freeze-dried powder injection. The busulfan nano-micelle comprises busulfan, phospholipid, cholate, a stabilizer and a protective agent. The nano-micelle freeze-dried powder injection is prepared from the busulfan nano-micelle prepared by the invention through a freeze-drying method. By preparing the nano-micelle, the purposes of reducing in-vivo toxicity of busulfan, reducing use of organic solvents and improving solubility and bioavailability of busulfan are achieved. The invention provides a novel busulfan preparation form, namely a micelle freeze-drying preparation form, so that the stability of the drug is improved, the toxicity of the drug is reduced, the solubility of the drug is increased, and the in-vivo bioavailability of the busulfan is improved.

The invention discloses application of dimethyl fumarate in preparation of a medicine for preventing and / or treating skeletal muscle atrophy, and belongs to the field of medicine. It is proved for the first time that DMF can effectively relieve related symptoms of skeletal muscle atrophy caused by cancer cachexia, and a new thought is provided for treatment of skeletal muscle atrophy. The DMF can relieve skeletal muscle atrophy by reducing mitochondrial damage and improving mitochondrial homeostasis imbalance, and the potential mechanism of the DMF is possibly related to the regulation of HIF1alpha, mTOR and other pathways. In addition, DMF can improve cancer cachexia skeletal muscle atrophy and does not inhibit tumor growth, which indicates that DMF directly acts on skeletal muscle instead of tumor. Due to the common end characteristic of mitochondrial homeostasis imbalance and the like in amyotrophy caused by different causes (such as aging and drug toxicity), the adjusting effect of DMF on homeostasis in skeletal muscle can be expanded to be used for preventing and treating other types of amyotrophy, including amyotrophy caused by aging, glucocorticoid, chemotherapy drugs and the like. The invention provides an application basis for preventing and treating skeletal muscle atrophy by DMF.

The invention relates to the field of medical application of biological hydrogel, in particular to dexamethasone loaded hydrogel delivered across tympanic membranes and a preparation method of the dexamethasone loaded hydrogel, the hydrogel takes gelatin Gel and dopamine modified hyaluronic acid HADA as base materials, a three-dimensional network structure is formed through enzymatic crosslinking of transglutaminase mTGase, dexamethasone sodium phosphate Dex is loaded, and the hydrogel can be used for preparing the dexamethasone loaded hydrogel. Furthermore, local trans-tympanic membrane middle ear drug delivery and release are realized; specifically, a solution A composed of Gel, HADA and Dex and a solution B composed of mTGase are evenly mixed according to the volume ratio of 4: 1 and dropwise added to the surface of the tympanic membrane through an external auditory canal, and finally Gel-HADA-Dex hydrogel is formed on the surface of the tympanic membrane. Local precise high-concentration drug delivery can be achieved, systemic drug toxicity is avoided, materials are safe, ear toxicity is avoided, meanwhile, adhesion performance is high, drug release is continuous, gradual self-degradation is achieved, manual taking out is not needed, and use convenience is remarkably improved.